CellVax
Singapore, Singapore· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $450M
Overview
An oncology company engineering cell-based vaccines and therapies to activate the immune system against cancer.
Oncology
Technology Platform
A cell engineering platform that creates personalized dendritic cell vaccines loaded with tumor antigens to stimulate a potent anti-cancer T-cell response.
Funding History
1Total raised:$450M
Series E$450M
Opportunities
Demonstrating efficacy in solid tumors, particularly as a combination therapy, could unlock significant value and partnership deals.
Risk Factors
The complexity and cost of personalized cell manufacturing present major hurdles for scalability and commercialization.
Competitive Landscape
Faces competition from other cell therapy approaches (CAR-T, TILs) and numerous cancer vaccine developers, both personalized and off-the-shelf.